ADC	Antibody-drug conjugate
ADCC	Antibody-dependent cell-mediated cytotoxicity
ALCL	Anaplastic large cell lymphoma
AlloSCT	Allogeneic stem cell transplantation
AMPK	AMP-activated protein kinase
Ara-C	Cytarabine
ASCT	Autologous stem cell transplantation
ATM	Ataxia teleangiectasia mutated
BCL2	B cell lymphoma 2
BCR	B-cell receptor
BH3	BCL2 homology 3
BL	Burkitt lymphoma
BMI-I	B-cell specific Moloney murine leukemia virus integration site 1
BTK	Bruton tyrosine-kinase
CAR	Chimeric antigen receptor
CDC	Complement-dependent cytotoxicity
CDK	Cyclin-dependent kinase
CLL	Chronic lymphocytic leukemia
CR	Complete remission
DCL	Deoxycytidine kinase
DDR	DNA damage response
DLBCL	Diffuse large B-cell lymphoma
HDT	High-dose therapy
EMEA	European Medicines Agency
FDA	Federal Drug Administration
FL	Follicular Lymphoma
MALT	Mucosa-associated lymphoid tissue
MCL	Mantle cell lymphoma
MMAE	Mono-methyl-auristatin E
MZL	Marginal zone lymphoma
MRD	Minimal residual disease
MTOR	Mammalian target of rapamycine
NFkappaB	Nuclear factor kappa B
NHL	Non-Hodgkin lymphoma
NK	Natural killer (cells)
ORR	Overall response rate (=complete and partial remissions)
OS	Overall survival
PARP1	poly(ADP)ribose-polymerase 1
PD(L)	Programmed cell death (ligand)
PFS	Progression-free survival
PI3K	Phosphoinositide-3 kinase
PIP2	phosphoinositide 4,5-diphosphate
PIP3	phosphoinositide 3,4,5-triphosphates
PLC	Phospholipase C
PPP	Pentose phosphate pathway
PR	Partial remission
PTEN	Phosphatase and tensin homolog
R-CHOP	Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone
R-DHAP	Rituximab + dexamethasone + high-dose cytarabine + cisplatin
RM	Rituximab maintenance
SHIP1	Src homology 2 containing inositol 5′ polyphosphatase 1